Syndax Pharmaceuticals, Inc. (SNDX) has a negative trailing P/E of -7.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 34.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -13.55%, forward earnings yield 2.92%. PEG 0.33 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.4 | 0.08 | 1.25 | 85.92 | 2.48% |
| 2017 | -3.0 | 0.66 | 1.76 | 87.26 | - |
| 2018 | -1.5 | -2.21 | 2.13 | 74.43 | - |
| 2019 | -4.8 | 0.13 | 8.47 | 176.47 | - |
| 2020 | -12.6 | 3.30 | 3.64 | 605.60 | - |
| 2021 | 45.7 | -0.36 | 2.79 | 8.16 | - |
| 2022 | -10.4 | 0.02 | 3.31 | 0.00 | - |
| 2023 | -7.3 | -0.34 | 2.74 | 0.00 | - |
| 2024 | -3.6 | -0.14 | 3.93 | 47.80 | - |
| 2025 | -6.4 | 0.55 | 28.16 | 10.56 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.04 | $1.22M | $-44.47M | -3645.2% |
| 2017 | $-2.90 | $2.11M | $-60.8M | -2884.3% |
| 2018 | $-2.92 | $1.52M | $-73.96M | -4875.5% |
| 2019 | $-1.84 | $1.52M | $-55.96M | -3688.5% |
| 2020 | $-1.77 | $1.52M | $-73.07M | -4816.7% |
| 2021 | $0.46 | $139.71M | $24.93M | 17.8% |
| 2022 | $-2.37 | $0.00 | $-143.75M | - |
| 2023 | $-2.98 | $0.00 | $-209.36M | - |
| 2024 | $-3.73 | $23.68M | $-318.76M | -1346.1% |
| 2025 | $-3.30 | $172.35M | $-285.42M | -165.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.84 | $-2.88 – $-0.68 | $360.39M | $334.3M – $413.97M | 9 |
| 2027 | $-0.66 | $-2.63 – $2.77 | $528.57M | $457.87M – $667.32M | 9 |
| 2028 | $0.72 | $-0.78 – $2.02 | $705.51M | $697.04M – $713.98M | 8 |
| 2029 | $1.81 | $1.43 – $2.37 | $908.37M | $763.08M – $1.13B | 6 |
| 2030 | $2.92 | $2.31 – $3.83 | $1.11B | $929.46M – $1.37B | 6 |
